96 related articles for article (PubMed ID: 24702815)
1. Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: a dose-response study.
Lucidi P; Porcellati F; Candeloro P; Cioli P; Andreoli AM; Marzotti S; Schmidt R; Bolli GB; Fanelli CG
Nutr Metab Cardiovasc Dis; 2014 Jul; 24(7):709-16. PubMed ID: 24702815
[TBL] [Abstract][Full Text] [Related]
2. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes.
Bolli GB; Hahn AD; Schmidt R; Eisenblaetter T; Dahmen R; Heise T; Becker RH
Diabetes Care; 2012 Dec; 35(12):2626-30. PubMed ID: 23093664
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: a single dose clamp study in people with type 2 diabetes.
Luzio SD; Dunseath GJ; Atkinson MD; Owens DR
Diabetes Metab; 2013 Dec; 39(6):537-42. PubMed ID: 24139704
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes.
Lucidi P; Porcellati F; Rossetti P; Candeloro P; Andreoli AM; Cioli P; Hahn A; Schmidt R; Bolli GB; Fanelli CG
Diabetes Care; 2012 Dec; 35(12):2647-9. PubMed ID: 23086139
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes.
Porcellati F; Lucidi P; Cioli P; Candeloro P; Marinelli Andreoli A; Marzotti S; Ambrogi M; Bolli GB; Fanelli CG
Diabetes Care; 2015 Mar; 38(3):503-12. PubMed ID: 25524950
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes.
Luzio SD; Beck P; Owens DR
Horm Metab Res; 2003 Jul; 35(7):434-8. PubMed ID: 12931275
[TBL] [Abstract][Full Text] [Related]
7. Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and igf-I receptor signaling.
Varewijck AJ; Yki-Järvinen H; Schmidt R; Tennagels N; Janssen JA
Diabetes; 2013 Jul; 62(7):2539-44. PubMed ID: 23569175
[TBL] [Abstract][Full Text] [Related]
8. Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.
Sørensen LP; Brock B; Mengel A; Rungby J; Moller N; Nielsen S; Vølund A; Schmitz O
Diabet Med; 2010 Jul; 27(7):830-7. PubMed ID: 20636965
[TBL] [Abstract][Full Text] [Related]
9. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes.
Koehler G; Treiber G; Wutte A; Korsatko S; Mader JK; Semlitsch B; Pieber TR
Diabetes Obes Metab; 2014 Jan; 16(1):57-62. PubMed ID: 23841569
[TBL] [Abstract][Full Text] [Related]
11. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.
Porcellati F; Rossetti P; Busciantella NR; Marzotti S; Lucidi P; Luzio S; Owens DR; Bolli GB; Fanelli CG
Diabetes Care; 2007 Oct; 30(10):2447-52. PubMed ID: 17623819
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes.
Luzio S; Dunseath G; Peter R; Pauvaday V; Owens DR
Diabetologia; 2006 Jun; 49(6):1163-8. PubMed ID: 16596358
[TBL] [Abstract][Full Text] [Related]
13. Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs.
Werner U; Tennagels N; Fanelli CG; Bolli GB
Diabetes Obes Metab; 2021 Jan; 23(1):166-174. PubMed ID: 33001554
[TBL] [Abstract][Full Text] [Related]
14. Dose-response effects of insulin glargine in type 2 diabetes.
Wang Z; Hedrington MS; Gogitidze Joy N; Briscoe VJ; Richardson MA; Younk L; Nicholson W; Tate DB; Davis SN
Diabetes Care; 2010 Jul; 33(7):1555-60. PubMed ID: 20357371
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes.
Hompesch M; Ocheltree SM; Wondmagegnehu ET; Morrow LA; Kollmeier AP; Campaigne BN; Jacober SJ
Curr Med Res Opin; 2009 Nov; 25(11):2679-87. PubMed ID: 19761358
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique.
Scholtz HE; Pretorius SG; Wessels DH; Becker RH
Diabetologia; 2005 Oct; 48(10):1988-95. PubMed ID: 16160867
[TBL] [Abstract][Full Text] [Related]
17. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects.
Sinha VP; Choi SL; Soon DK; Mace KF; Yeo KP; Lim ST; Howey DC
J Clin Pharmacol; 2014 Jul; 54(7):792-9. PubMed ID: 24504686
[TBL] [Abstract][Full Text] [Related]
18. Insulin glargine metabolite 21(A) -Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study.
Danne T; Becker RH; Ping L; Philotheou A
Pediatr Diabetes; 2015 Jun; 16(4):299-304. PubMed ID: 25041275
[TBL] [Abstract][Full Text] [Related]
19. More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naïve patients with type 2 diabetes mellitus.
Polonsky W; Traylor L; Wei W; Shi R; Ameer B; Vlajnic A; Nicolucci A
Diabetes Obes Metab; 2014 Mar; 16(3):255-61. PubMed ID: 24028669
[TBL] [Abstract][Full Text] [Related]
20. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml.
Steinstraesser A; Schmidt R; Bergmann K; Dahmen R; Becker RH
Diabetes Obes Metab; 2014 Sep; 16(9):873-6. PubMed ID: 24571126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
